糜蛋白酶C在胰腺炎和胰腺癌发生发展中的作用

刘泽杰; 宋沂林; 李红; 冯英明; 苏海川

doi:10.3969/j.issn.1001-5256.2016.11.051

糜蛋白酶C在胰腺炎和胰腺癌发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2016.11.051

第四军医大学附属唐都医院肿瘤科

基金项目:

国家自然科学基金资助项目(3157080036)；

详细信息

中图分类号: R576;R735.9
计量
- 文章访问数: 2114
- HTML全文浏览量: 21
- PDF下载量: 467
- 被引次数: 0
出版历程
- 收稿日期: 2016-05-26
- 出版日期: 2016-11-20

Role of chymotrypsin C in development and progression of pancreatitis and pancreatic cancer

Department of Oncology,Tangdu Hospital,Fourth Military Medical University

Research funding:

摘要

摘要: 糜蛋白酶C(CTRC)是由胰腺腺泡细胞合成,胰腺导管细胞分泌的蛋白酶原,属于丝氨酸糜蛋白酶家族。其主要作用是调控胰蛋白酶的活化与降解的平衡,维持胰腺组织结构和功能的完整性。CTRC基因位点突变,使得胰蛋白酶原的活化及胰蛋白酶的降解异常,导致慢性胰腺炎的发生。CTRC表达下调甚至缺失可能与胰腺癌的发生及转移有关。介绍了CTRC基因的结构、生物学功能,及其在胰腺炎、胰腺癌发生发展中的作用机制。
- 糜蛋白酶 /
- 胰腺炎 /
- 胰腺肿瘤 /
- 综述
Abstract: Chymotrypsin C( CTRC) is a trypsinogen synthesized by pancreatic acinar cells and secreted by pancreatic duct cells and belongs to the family of serine chymotrypsin. The main function of CTRC is to regulate the balance between activation and degradation of trypsin and maintain the structural and functional integrity of the pancreas. CTRC gene mutations can cause abnormal activation of trypsinogen and abnormal degradation of trypsin and then lead to the development of pancreatitis. The downregulation or absence of CTRC expression may be associated with the development and metastasis of pancreatic cancer. This article introduces the structure and biological function of CTRC and its mechanism of action in the development and progression of pancreatitis and pancreatic cancer.
- chymotrypsin /
- pancreatitis /
- pancreatic neoplasms /
- review

HTML全文

参考文献(35)

[1]PEERY AF,DELLON ES,LUND J,et al.Burden of gastrointestinal disease in the United States:2012 update[J].Gastroenterology,2012,143(5):1179-1187.

[2]SIEGEL R,NAISHADHAM D,JEMAL A.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30

[3]MA C,JIANG YX,LIU SZ,et al.Trend and prediction on the incidence of pancreatic cancer in China[J].Chin J Epidemiol,2013,34(2):160-163.(in Chinese)马臣,姜永晓,刘曙正,等.中国胰腺癌发病趋势分析和预测[J].中华流行病学杂志,2013,34(2):160-163.

[4]ZHANG L,ZHAN Z.Change of TCM tongue coating and syndromes of patients with pancreatic cancer before and after chemotherapy[J].J Changchun Univ Chin Med,2016,32(1):108-110.(in Chinese)张莉,詹7).胰腺癌患者化疗前后中医舌象及证型变化研究[J].长春中医药大学学报,2016,32(1):108-110.

[5]SZMOLA R,SAHIN-TOTH M.Pancreatitis-associated chymotrypsinogen C(CTRC)mutant elicits endoplasmic reticulum stress in pancreatic acinar cel s[J].Gut,2010,59(3):365-372.

[6]ROSENDAH J,WITT H,SZMOLA R,et al.Chymotrypsin C(CTRC)variants that diminish activity or secretion are associated with chronic pancreatitis[J].Nat Genet,2008,40(1):78-82.

[7]WANG H,SHA W,LIN Z,et al.Effect of chymotrypsin C and related proteins on pancreatic cancer cell migration[J].Acta Biochim Biophys Sin(Shanghai),2011,43(5):362-371.

[8]ZSOFIA NEMODA,MIKLS SAHIN-TTH.Chymotrypsin C(caldecrin)stimulates autoactivation of huaman catonic trypsinogen[J].J Biol Chem,2006,281(17):11879-11886.

[9]IIO-AKAMA K,SASAMOTO H,MIYAZAWA K,et al.Active forms of chymotrypsin C isolated from autolyzed porcine pancreas glands[J].Biochim Biophys Acta,1985,831(2):249-256.

[10]BINKER MG,RICHARDS D,GAISANO HY,et al.ER stress-associated CTRC mutants decrease stimulated pancreatic zymogen secretion through SIRT2-mediated microtubule dysregulation[J].Biochem Biophys Res Commun,2015,463(3):329-335.

[11]NEMODA Z,SAHIN-TOTH M.The tetra-aspartate motif in the activation peptide of human cationictrypsinogen is essential for autoactivation control but not for enteropeptidase recognition[J].J Biol Chem,2005,280(33):29645-29652.

[12]KEIL-DLOUHA V,PUIGSERVER A,MARIE A,et al.On subunit II of bovine procarboxypeptidase A.Enzymatic specificity after tryptic activation[J].Biochim Biophys Acta,1972,276(2):531-535.

[13]FOLK JE,COLE PW.ChymotrypsinC.II.Enzymatic specificity toward several polypeptides[J].J Biol Chem,1965,240:193-197.

[14]SZMOLA R,SAHIN-TOTH M.Chymotrypsin C(caldecrin)promotes degradation of human cationic trypsin:identity with Rinderknecht's enzyme Y[J].Proc Natl Acad Sci U S A,2007,104(27):11227-11232.

[15]TOMOMURA A,TOMOMURA M,FUKUSHIGE T,et al.Molecular cloning and expression of serum calcium-decreasing factor(caldecrin)[J].J Biol Chem,1995,270(51):30315-30321.

[16]KOZIEL D,GLUSZEK S,KOWALIK A,et al.Genetic mutations in SPINK1,CFTR,CTRC genes in acute pancreatitis[J].BMC Gastroenterology,2015,15:70.

[17]PALERMO JJ,LIN TK,HORNUNG L,et al.Genophenotypic analysis of pediatric patients with acute recurrent and chronic pancreatitis[J].Pancreas,2016.[Epub ahead of print]

[18]WERLIN S,KONIKOFF FM,HALPERN Z,et al.Genetic and electrophysiological characteristics of recurrent acute pancreatitis[J].J Pediatr Gastroenterol Nutr,2015,60(5):675-679.

[19]LARUSCH J,LOZANO-LEON A,STELLO K,et al.The common chymotrypsinogen C(CTRC)variant G60G(C.180T)increases risk of chronic pancreatitis but not recurrent acute pancreatitis in a North American population[J].Clin Transl Gastroenterol,2015,6:e68.

[20]TREMBLAY K,DUBOIS-BOUCHARD C,BRISSON D,et al.Association of CTRC and SPINK1 gene variants with recurrent hospitalizations for pancreatitis or acute abdominal pain in lipoprotein lipase deficiency[J].Front Genet,2014,5:90.

[21]LARUSCH J,WHITCOMB DC.Genetics of pancreatitis[J].Curr Opin Gastroenterol,2011,27(5):467-474.

[22]RAVI KANTH V,NAGESHWAR REDDY D.Genetics of acute and chronic pancreatitis:an update[J].World J Gastrointest Pathophysiol,2014,5(4):427-437.

[23]BEER S,ZHOU J,SZABO A,et al.Comprehensive functional analysis of chymotrypsin C(CTRC)variants reveals distinct loss-of-function mechanisms associated with pancreatitis risk[J].Gut,2013,62(11):1616-1624.

[24]DERIKX MH,DRENTH JP.Drenth genetic factors in chronic pancreatitis;implications for diagnosis,management and prognosis[J].Best Pract Res Clin Gastroenterol,2010,24(3):251-270.

[25]ZHANG N,WANG YX,HU J,et al.Application of levels of serum CA199,C3,C4 and lipid metabolism in clinical diagnosis of pancreatic cancer[J].J Jilin Univ:Med Edit,2016,42(2):295-300.(in Chinese)张宁,王颖娴,胡健,等.血清CA199、C3、C4及脂类代谢水平在胰腺癌临床诊断中的应用[J].吉林大学学报:医学版,2016,42(2):295-300.

[26]GUO XZ,LIU X.Discussion of difficult problems of early diagnosis of pancreatic cancer[J].J Clin Hepatol,2014,30(8):734-736.(in Chinese)郭晓钟,刘旭.胰腺癌早期诊断难点的思考[J].临床肝胆病杂志,2014,30(8):734-736.

[27]PANKOV R,UMEZAWA A,MAKI R,et al.Oncogene activation of human keratin 18 transcription via the Ras signal transduction pathway[J].Proc Natl Acad Sci U S A,1994,91(3):873-877.

[28]MESSAI Y,NOMAN MZ,DEROUICHE A,et al.Cytokeratin18 expression pattern correlates with renal cell carcinoma progression:relationship with Snail[J].Int J Oncol,2010,36(5):1145-1154.

[29]STIGBRAND T.The versatility of cytokeratins as tumor markers[J].Tumour Biol,2001,22(1):1-3.

[30]KULESH DA,OSHIMA RG.Cloning of the human keratin 18gene and its expression in nonepithelial mouse cells[J].Mol Cell Biol,1988,8(4):1540-1550.

[31]SCHAAFSMA HE,RAMAEKERS FC,van MUIJEN GN,et al.Distribution of cytokeratin polypeptides in human transitional cell carcinomas,with special emphasis on changing expression patterns during tumor progression[J].Am J Pathol,1990,136(2):329-343.

[32]TRASK DK,BAND V,ZAJCHOWSKI DA,et al.Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells[J].Proc Natl Acad Sci U S A,1990,87(6):2319-2323.

[33]DEBUS E,MOLL R,FRANKE WW,et al.Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies[J].Am J Pathol,1984,114(1):121-130.

[34]CHU YW,YANG PC,YANG SC,et al.Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line[J].Am J Respir Cell Mol Biol,1997,17(3):353-360.

[35]DIVE C,SMITH RA,GARNER E,et al.Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer[J].Br J Cancer,2010,102(3):577-582.

施引文献

资源附件(0)

访问统计